There are bioinformatics indications that the expression of LGALS16 changes in association with Alzheimer’s disease, chronic myeloid leukemia, breast cancer, B-cell lymphoma, and type 2 diabetes. This evidence concerns the gene LGALS16 and breast carcinoma.